Related Experiment Video
Updated: Sep 27, 2026

Ultrasound Cyclo Plasty in Eyes with Glaucoma
Published on: January 26, 2018
[Mitomycin C in glaucoma filtering surgery]
1Ocní klinika FN, Hradec Králové.
Abstract:
Authors evaluate application of mitomycin C (0.2-0.4 mg/ml) on the sclera during glaucoma filtering surgery. Mean follow-up was 19.5 months in the group of 67 patients (75 eyes). The most serious complication was an early endophthalmitis in 2 cases with the loss of residual visual field and vision, 1x hemophthalmus followed with the development of traction retinal detachment, 1x hypotonic maculopathy, 1x traction retinal detachment for progression of proliferative vitreoretinopathy of neovascular glaucoma. Higher rate of the complications was noted in the group of mitomycin C 0.4 mg/l. Visual acuity was better one line Snellen optotypes in 3 cases, and worse in 26 cases. Intraocular pressure (IOP) compensation up to 20 mmHg was reached in 32 cases without therapy (45.1%), in 28 cases therapy, (39.6%). IOP above 20 mmHg was in 11 cases (15.4%) and the data are not known in 4 cases (5.41%). IOP was compensated after mitomycin C application in 84.7%.
Insights
Mitomycin C application during glaucoma surgery showed an 84.7% intraocular pressure compensation rate. However, higher concentrations (0.4 mg/ml) increased complication risks, including vision loss.
Area of Science:
- Ophthalmology
- Surgical Innovation
Context:
- Glaucoma filtering surgery aims to reduce intraocular pressure (IOP).
- Mitomycin C is an antimetabolite used to enhance surgical outcomes.
- Evaluating the efficacy and safety of mitomycin C in glaucoma surgery is crucial.
Purpose:
- To assess the effectiveness of topical mitomycin C (0.2-0.4 mg/ml) in glaucoma filtering surgery.
- To analyze the complication rates and visual acuity changes associated with mitomycin C use.
- To determine the intraocular pressure (IOP) control achieved with mitomycin C application.
Summary:
- This study evaluated 67 patients (75 eyes) undergoing glaucoma surgery with mitomycin C, with a mean follow-up of 19.5 months.
- Intraocular pressure (IOP) compensation was achieved in 84.7% of cases post-mitomycin C application.
- Serious complications, such as endophthalmitis and retinal detachment, were noted, particularly at the higher concentration of 0.4 mg/ml.
Impact:
- Mitomycin C demonstrates significant potential for IOP control in glaucoma surgery.
- Careful consideration of mitomycin C concentration is necessary to minimize serious adverse events.
- Further research may optimize mitomycin C protocols for improved glaucoma treatment outcomes.
Related Concept Videos
Glaucoma: Overview
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment

